Tegsedi market seen growing on personalized medicine and genetic testing

The Business Research Company says the Tegsedi market is being reshaped by personalized medicine, genetic testing and broader healthcare spending, with North America leading the global market in 2025. The report points to rising demand for home-based treatment, RNA-targeted therapies and precision diagnostics through 2035.

Why it matters: - Tegsedi is a treatment for hereditary transthyretin-mediated amyloidosis, a rare genetic disease that damages nerves. - The market’s growth reflects wider demand for targeted therapies that match a patient’s genetic profile. - The report frames Tegsedi as part of a broader shift toward self-administered and disease-modifying rare-disease medicines.

What happened: - The Business Research Company released its "Tegsedi Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035." - The report says the Tegsedi market is changing because of advances in genetic research and treatment innovation. - The report identifies North America as the dominant region in the global Tegsedi market for 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - Tegsedi, or inotersen, is a weekly subcutaneous injection for adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. - The drug works by inhibiting production of the transthyretin protein, which reduces amyloid deposits and eases neuropathic symptoms. - The report says historical market growth was driven by better understanding of hereditary amyloidosis, more genetic testing programs, regulatory approvals for antisense therapies and stronger specialist neurology networks. - Early clinical success with transthyretin suppression drugs also helped the market expand. - The forecast period is expected to benefit from wider use of personalized genetic medicines and greater demand for home-based treatment options. - Additional growth factors include precision diagnostics, more investment in RNA therapeutics and better long-term safety monitoring systems. - The report highlights rising use of RNA-targeted therapies, a shift toward self-administration and more focus on disease-modifying medicines and patient safety protocols. - The report includes new features such as market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - The report offers a free sample here. - The full report is available here.

Between the lines: - Personalized medicine is becoming a bigger commercial driver because genetic testing and diagnostics make it easier to match treatments to rare-disease patients. - The report points to healthcare spending as a market enabler because higher budgets can widen access to advanced therapies. - U.S. healthcare spending rose 7.5% in 2023 to $4.9 trillion, or about $14,570 per person, according to Centers for Medicare & Medicaid Services data cited in the release. - The release also cites the Personalized Medicine Coalition as reporting that the U.S. Food and Drug Administration approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022.

What's next: - The report expects the Tegsedi market to keep expanding through 2035 as precision medicine, RNA therapeutics and home-based care gain traction. - More adoption of long-term safety monitoring systems could shape how the therapy is used in practice. - Regional performance beyond North America will depend on access to genetic testing, specialist care and reimbursement for rare-disease drugs.

The bottom line: - Tegsedi’s outlook is tied less to a single drug and more to the broader rise of genetic testing, personalized treatment and rare-disease infrastructure.